Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
2 hedge funds and large institutions have $2.03K invested in Genetic Technologies Ltd. in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
21% less capital invested
Capital invested by funds: $2.55K → $2.03K (-$527)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$528 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
RhumbLine Advisers
Boston,
Massachusetts
| $2.03K | -$528 | -690 | -21% |
|
GENE Hedge Fund Activity: Q3 2025 in Review
2 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q3 2025, worth a combined $2.03K — down 21% from $2.55K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new GENE positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest seller was RhumbLine Advisers, cutting an estimated $528.
- 2 institutional investors held Genetic Technologies Ltd. (GENE) as of Q3 2025, up from 1 in Q2 2025.
- Funds reported $2.03K of Genetic Technologies Ltd. stock for Q3 2025, down 21% quarter-over-quarter.
- 1 fund opened new Genetic Technologies Ltd. positions in Q3 2025 and 0 closed out, a net change of +1 holder.
- The largest Genetic Technologies Ltd. seller in Q3 2025 was RhumbLine Advisers, an estimated $528 sold.
Based on aggregated 13F filings for Q3 2025.